© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
After a priority 6-month review, the FDA approved nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories), a novel nonsteroidal anti-inflammatory prodrug, for the treatment of pain and inflammation associated with cataract surgery.